vs

Side-by-side financial comparison of PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (PACB) and REGIS CORP (RGS). Click either name above to swap in a different company.

REGIS CORP is the larger business by last-quarter revenue ($57.1M vs $44.6M, roughly 1.3× PACIFIC BIOSCIENCES OF CALIFORNIA, INC.). REGIS CORP runs the higher net margin — 0.8% vs -90.4%, a 91.2% gap on every dollar of revenue. On growth, REGIS CORP posted the faster year-over-year revenue change (22.3% vs 13.8%). REGIS CORP produced more free cash flow last quarter ($891.0K vs $-19.9M). Over the past eight quarters, REGIS CORP's revenue compounded faster (7.8% CAGR vs 7.3%).

Pacific Biosciences of California, Inc. is an American biotechnology company founded in 2004 that develops and manufactures systems for gene sequencing and some novel real time biological observation. PacBio has two principal sequencing platforms: single-molecule real-time sequencing (SMRT), based on the properties of zero-mode waveguides and sequencing by binding (SBB) chemistry, which uses native nucleotides and scarless incorporation for DNA binding and extension.

Regis Corporation is an American operator of hair salons. As of August 2021, it has 5,563 franchised and 276 company-owned salons. Its headquarters are in Minneapolis, Minnesota.

PACB vs RGS — Head-to-Head

Bigger by revenue
RGS
RGS
1.3× larger
RGS
$57.1M
$44.6M
PACB
Growing faster (revenue YoY)
RGS
RGS
+8.4% gap
RGS
22.3%
13.8%
PACB
Higher net margin
RGS
RGS
91.2% more per $
RGS
0.8%
-90.4%
PACB
More free cash flow
RGS
RGS
$20.8M more FCF
RGS
$891.0K
$-19.9M
PACB
Faster 2-yr revenue CAGR
RGS
RGS
Annualised
RGS
7.8%
7.3%
PACB

Income Statement — Q4 FY2025 vs Q2 FY2026

Metric
PACB
PACB
RGS
RGS
Revenue
$44.6M
$57.1M
Net Profit
$-40.4M
$456.0K
Gross Margin
37.1%
Operating Margin
-92.3%
10.8%
Net Margin
-90.4%
0.8%
Revenue YoY
13.8%
22.3%
Net Profit YoY
-1802.7%
-94.0%
EPS (diluted)
$-0.11
$0.16

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
PACB
PACB
RGS
RGS
Q4 25
$44.6M
$57.1M
Q3 25
$38.4M
$59.0M
Q2 25
$39.8M
$60.4M
Q1 25
$37.2M
$57.0M
Q4 24
$39.2M
$46.7M
Q3 24
$40.0M
$46.1M
Q2 24
$36.0M
$49.4M
Q1 24
$38.8M
$49.2M
Net Profit
PACB
PACB
RGS
RGS
Q4 25
$-40.4M
$456.0K
Q3 25
$-38.0M
$1.4M
Q2 25
$-41.9M
$116.5M
Q1 25
$-426.1M
$250.0K
Q4 24
$2.4M
$7.6M
Q3 24
$-60.7M
$-853.0K
Q2 24
$-173.3M
$91.2M
Q1 24
$-78.2M
$-2.3M
Gross Margin
PACB
PACB
RGS
RGS
Q4 25
37.1%
Q3 25
41.4%
Q2 25
36.9%
Q1 25
-3.7%
Q4 24
25.6%
Q3 24
25.0%
Q2 24
16.5%
Q1 24
29.1%
Operating Margin
PACB
PACB
RGS
RGS
Q4 25
-92.3%
10.8%
Q3 25
-101.1%
10.0%
Q2 25
-112.8%
12.1%
Q1 25
-1154.5%
8.8%
Q4 24
-390.1%
11.8%
Q3 24
-160.3%
4.6%
Q2 24
-488.3%
Q1 24
-209.6%
8.3%
Net Margin
PACB
PACB
RGS
RGS
Q4 25
-90.4%
0.8%
Q3 25
-98.9%
2.3%
Q2 25
-105.4%
192.9%
Q1 25
-1146.8%
0.4%
Q4 24
6.0%
16.4%
Q3 24
-151.9%
-1.9%
Q2 24
-481.3%
184.7%
Q1 24
-201.4%
-4.7%
EPS (diluted)
PACB
PACB
RGS
RGS
Q4 25
$-0.11
$0.16
Q3 25
$-0.13
$0.49
Q2 25
$-0.14
$43.67
Q1 25
$-1.44
$0.08
Q4 24
$-0.44
$2.71
Q3 24
$-0.22
$-0.36
Q2 24
$-0.64
$38.40
Q1 24
$-0.29
$-1.00

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
PACB
PACB
RGS
RGS
Cash + ST InvestmentsLiquidity on hand
$279.5M
$18.4M
Total DebtLower is stronger
$113.3M
Stockholders' EquityBook value
$5.3M
$188.7M
Total Assets
$784.1M
$588.3M
Debt / EquityLower = less leverage
0.60×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
PACB
PACB
RGS
RGS
Q4 25
$279.5M
$18.4M
Q3 25
$298.7M
$16.6M
Q2 25
$314.7M
$17.0M
Q1 25
$343.1M
$13.3M
Q4 24
$389.9M
$10.2M
Q3 24
$471.1M
$6.3M
Q2 24
$509.8M
$10.1M
Q1 24
$561.9M
$5.9M
Total Debt
PACB
PACB
RGS
RGS
Q4 25
$113.3M
Q3 25
$111.3M
Q2 25
$110.8M
Q1 25
$112.0M
Q4 24
$111.5M
Q3 24
$95.2M
Q2 24
$99.5M
Q1 24
$179.7M
Stockholders' Equity
PACB
PACB
RGS
RGS
Q4 25
$5.3M
$188.7M
Q3 25
$36.1M
$187.6M
Q2 25
$61.5M
$185.6M
Q1 25
$91.6M
$68.6M
Q4 24
$506.6M
$66.7M
Q3 24
$453.1M
$56.4M
Q2 24
$492.7M
$56.8M
Q1 24
$649.0M
$-35.8M
Total Assets
PACB
PACB
RGS
RGS
Q4 25
$784.1M
$588.3M
Q3 25
$803.2M
$592.1M
Q2 25
$825.5M
$599.0M
Q1 25
$860.8M
$511.2M
Q4 24
$1.3B
$530.1M
Q3 24
$1.5B
$508.9M
Q2 24
$1.5B
$530.5M
Q1 24
$1.7B
$543.7M
Debt / Equity
PACB
PACB
RGS
RGS
Q4 25
0.60×
Q3 25
0.59×
Q2 25
0.60×
Q1 25
1.63×
Q4 24
1.67×
Q3 24
1.69×
Q2 24
1.75×
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
PACB
PACB
RGS
RGS
Operating Cash FlowLast quarter
$-19.1M
$1.7M
Free Cash FlowOCF − Capex
$-19.9M
$891.0K
FCF MarginFCF / Revenue
-44.6%
1.6%
Capex IntensityCapex / Revenue
1.9%
1.4%
Cash ConversionOCF / Net Profit
3.65×
TTM Free Cash FlowTrailing 4 quarters
$-114.1M
$14.9M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
PACB
PACB
RGS
RGS
Q4 25
$-19.1M
$1.7M
Q3 25
$-18.7M
$2.3M
Q2 25
$-29.4M
$6.8M
Q1 25
$-44.1M
$6.2M
Q4 24
$-30.6M
$2.1M
Q3 24
$-45.5M
$-1.3M
Q2 24
$-54.3M
$5.1M
Q1 24
$-75.7M
$-277.0K
Free Cash Flow
PACB
PACB
RGS
RGS
Q4 25
$-19.9M
$891.0K
Q3 25
$-18.8M
$1.9M
Q2 25
$-29.9M
$6.2M
Q1 25
$-45.4M
$5.9M
Q4 24
$-32.3M
$1.7M
Q3 24
$-46.3M
$-1.4M
Q2 24
$-55.7M
$5.1M
Q1 24
$-79.6M
$-326.0K
FCF Margin
PACB
PACB
RGS
RGS
Q4 25
-44.6%
1.6%
Q3 25
-48.9%
3.2%
Q2 25
-75.3%
10.3%
Q1 25
-122.3%
10.3%
Q4 24
-82.3%
3.6%
Q3 24
-115.7%
-3.0%
Q2 24
-154.8%
10.3%
Q1 24
-205.0%
-0.7%
Capex Intensity
PACB
PACB
RGS
RGS
Q4 25
1.9%
1.4%
Q3 25
0.2%
0.7%
Q2 25
1.4%
0.9%
Q1 25
3.7%
0.6%
Q4 24
4.1%
0.9%
Q3 24
2.0%
0.0%
Q2 24
4.1%
0.0%
Q1 24
10.0%
0.1%
Cash Conversion
PACB
PACB
RGS
RGS
Q4 25
3.65×
Q3 25
1.68×
Q2 25
0.06×
Q1 25
24.80×
Q4 24
-12.93×
0.28×
Q3 24
Q2 24
0.06×
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

PACB
PACB

Products$39.0M87%
Service And Other$5.7M13%

RGS
RGS

Franchise Segment$37.9M66%
Royalty$13.6M24%
Other$2.8M5%
Fees$1.8M3%
Franchise Fees$1.0M2%

Related Comparisons